Henlius: using a fully integrated platform to advance high-quality, affordable biologics

With its dynamic end-to-end in-house capabilities, Henlius has developed a unique pipeline of cancer and autoimmune drugs, including HLX01, a biosimilar version of MabThera. The company is now exploring the creation of further biosimilars and immuno-oncology combination therapies

Go to the profile of Henlius
Nov 21, 2019
0
0
Page of
Go to the profile of Henlius

Henlius

Henlius is a leading biopharmaceutical company in China focusing on oncology and autoimmune diseases with the vision to offer high-quality, affordable and innovative biologics for patients worldwide. Founded in 2010 and headquartered in Shanghai, we have built an integrated and efficient global R&D platform with key facilities in Shanghai, Taipei and California collaborating with each other to ensure the highly productive and cost-efficient R&D processes. Discovering new ways to improve and extend patients’ lives by driving access to high-quality biologics worldwide, we are committed to biosimilar, innovative monoclonal antibody (mAb) products and immuno-oncology combination therapies with proprietary anti-PD-1/PD-L1 mAbs as backbone on an integrated platform covering the entire product lifecycle from R&D, commercial-scale production to commercialization. On September 25, 2019, We were successfully listed and commenced trading on the Main Board of the Stock Exchange of Hong Kong Limited under the stock code 2696.HK.

No comments yet.